AstraZeneca's Crestor: Challenges in the US Market




Code : COM0047
|
Region : USA
|
||||
![]() |
![]() |
![]() |
![]() OR |
Abstract:
London-based drug maker, AstraZeneca, is the fourth largest in the world and second largest in Europe. When the company announced its plans to enter the cholesterol-lowering drugs segment (also called statins) with Crestor in the US, it received mixed responses from the industry and analysts. |
|
For Case Books
Click Here >> For Case eBooks Click Here >> |
Pedagogical Objectives:
Keywords : AstraZeneca; Cholesterol-lowering drugs (statins); Blockbuster drugs; Crestor; Lipitor; Baycol controversy; Negative sentiments; Pfizer's marketing; Merck's Zocor; Bristol-Myers Squibb's Pravachol; Marketing budgets; FDA approvals (Federal Drug Administration); Managing in Troubled Times Case Study; Merck's Vytorin; The Lancet; Clinical tests
Contents :
» The Statin Market
» Crestor - Another Statin?
» The Statin Dillemma